Status:
UNKNOWN
Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
Lead Sponsor:
Chakshu Research, Inc.
Conditions:
Nuclear Cataract
Eligibility:
All Genders
35-90 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
Eligibility Criteria
Inclusion
- Presence of nuclear sclerosis cataract
- BCDVA within the range of 20/40 and 20/80
Exclusion
- Any other clinical condition in the eye that may compromise vision
- Presence or history of glaucoma
- Presence or history of diabetes
- Use of eyedrops
- Use of steroids
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00825721
Start Date
November 1 2007
End Date
September 1 2009
Last Update
January 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tilganga Eye Center
Kathmandu, Kathmandu, Nepal